Establishment of a rat model of uric acid nephropathy

doi:10. 3969 / j.issn.1671-7856. 2022. 02. 001

Home > Archive>Volume 32, Issue 2, 2022 >1-9. DOI:10. 3969 / j.issn.1671-7856. 2022. 02. 001

Establishment of a rat model of uric acid nephropathy
DOI:
                        10. 3969 / j.issn.1671-7856. 2022. 02. 001
                    
CSTR:
                        [cstr]
                    
Author:
                        YAN MeixiaYAN Meixia
1. State Key Laboratory of Dampness Syndrome of Chinese Medicine, the Second Affiliated Hospital of Guangzhou University of Chinese Medicine, (the Second Clinical Medical College of Guangzhou University of Chinese Medicine), Guangzhou 510006, China. 2. Department of Nephrology, Henan Provincial People’s Hospital, Department of Nephrology of Central China Fuwai Hospital, Zhengzhou 450003. 3. Department of Nephrology, Guangdong Provincial Hospital of Chinese Medicine, Guangzhou 510006.
Find this author on All Journals
Find this author on BaiDu
Search for this author on this site
HUO ShuaiHUO Shuai
1. State Key Laboratory of Dampness Syndrome of Chinese Medicine, the Second Affiliated Hospital of Guangzhou University of Chinese Medicine, (the Second Clinical Medical College of Guangzhou University of Chinese Medicine), Guangzhou 510006, China. 2. Department of Nephrology, Henan Provincial People’s Hospital, Department of Nephrology of Central China Fuwai Hospital, Zhengzhou 450003.4. Department of Nephrology, Henan Provincial People’s Hospital, Department of Nephrology of Central Fuwai Hospital, Zhengzhou 450003.
Find this author on All Journals
Find this author on BaiDu
Search for this author on this site
TIAN RuiminTIAN Ruimin
1. State Key Laboratory of Dampness Syndrome of Chinese Medicine, the Second Affiliated Hospital of Guangzhou University of Chinese Medicine, (the Second Clinical Medical College of Guangzhou University of Chinese Medicine), Guangzhou 510006, China. 2. Department of Nephrology, Henan Provincial People’s Hospital, Department of Nephrology of Central China Fuwai Hospital, Zhengzhou 450003. 3. Department of Nephrology, Guangdong Provincial Hospital of Chinese Medicine, Guangzhou 510006.5. Guangdong Provincial Key Laboratory of Chinese Medicine for Prevention and Treatment of Refractory Chronic Diseases, Guangzhou 51006.
Find this author on All Journals
Find this author on BaiDu
Search for this author on this site
XU PengXU Peng
1. State Key Laboratory of Dampness Syndrome of Chinese Medicine, the Second Affiliated Hospital of Guangzhou University of Chinese Medicine, (the Second Clinical Medical College of Guangzhou University of Chinese Medicine), Guangzhou 510006, China. 2. Department of Nephrology, Henan Provincial People’s Hospital, Department of Nephrology of Central China Fuwai Hospital, Zhengzhou 450003. 3. Department of Nephrology, Guangdong Provincial Hospital of Chinese Medicine, Guangzhou 510006.5. Guangdong Provincial Key Laboratory of Chinese Medicine for Prevention and Treatment of Refractory Chronic Diseases, Guangzhou 51006.
Find this author on All Journals
Find this author on BaiDu
Search for this author on this site
LI ChuangLI Chuang
1. State Key Laboratory of Dampness Syndrome of Chinese Medicine, the Second Affiliated Hospital of Guangzhou University of Chinese Medicine, (the Second Clinical Medical College of Guangzhou University of Chinese Medicine), Guangzhou 510006, China. 2. Department of Nephrology, Henan Provincial People’s Hospital, Department of Nephrology of Central China Fuwai Hospital, Zhengzhou 450003. 3. Department of Nephrology, Guangdong Provincial Hospital of Chinese Medicine, Guangzhou 510006.5. Guangdong Provincial Key Laboratory of Chinese Medicine for Prevention and Treatment of Refractory Chronic Diseases, Guangzhou 51006.
Find this author on All Journals
Find this author on BaiDu
Search for this author on this site
HU TianxiangHU Tianxiang
2.Department of Nephrology, Henan Provincial People’s Hospital, Department of Nephrology of Central China Fuwai Hospital, Zhengzhou 450003. 3. Department of Nephrology, Guangdong Provincial Hospital of Chinese Medicine, Guangzhou 510006.
Find this author on All Journals
Find this author on BaiDu
Search for this author on this site
CHEN DahaoCHEN Dahao
1. State Key Laboratory of Dampness Syndrome of Chinese Medicine, the Second Affiliated Hospital of Guangzhou University of Chinese Medicine, (the Second Clinical Medical College of Guangzhou University of Chinese Medicine), Guangzhou 510006, China. 2. Department of Nephrology, Henan Provincial People’s Hospital, Department of Nephrology of Central China Fuwai Hospital, Zhengzhou 450003. 3. Department of Nephrology, Guangdong Provincial Hospital of Chinese Medicine, Guangzhou 510006.
Find this author on All Journals
Find this author on BaiDu
Search for this author on this site
CHEN XiaolingCHEN Xiaoling
1. State Key Laboratory of Dampness Syndrome of Chinese Medicine, the Second Affiliated Hospital of Guangzhou University of Chinese Medicine, (the Second Clinical Medical College of Guangzhou University of Chinese Medicine), Guangzhou 510006, China. 2. Department of Nephrology, Henan Provincial People’s Hospital, Department of Nephrology of Central China Fuwai Hospital, Zhengzhou 450003. 3. Department of Nephrology, Guangdong Provincial Hospital of Chinese Medicine, Guangzhou 510006.
Find this author on All Journals
Find this author on BaiDu
Search for this author on this site
MAO WeiMAO Wei
1. State Key Laboratory of Dampness Syndrome of Chinese Medicine, the Second Affiliated Hospital of Guangzhou University of Chinese Medicine, (the Second Clinical Medical College of Guangzhou University of Chinese Medicine), Guangzhou 510006, China. 2. Department of Nephrology, Henan Provincial People’s Hospital, Department of Nephrology of Central China Fuwai Hospital, Zhengzhou 450003. 3. Department of Nephrology, Guangdong Provincial Hospital of Chinese Medicine, Guangzhou 510006.6. Guangdong Provincial Key Laboratory of Clinical Research on Traditional Chinese Medicine Syndrome, Guangzhou 51006
Find this author on All Journals
Find this author on BaiDu
Search for this author on this site

                    
Affiliation:1. State Key Laboratory of Dampness Syndrome of Chinese Medicine, the Second Affiliated Hospital of Guangzhou University of Chinese Medicine, (the Second Clinical Medical College of Guangzhou University of Chinese Medicine), Guangzhou 510006, China. 2. Department of Nephrology, Henan Provincial People’s Hospital, Department of Nephrology of Central China Fuwai Hospital, Zhengzhou 450003. 3. Department of Nephrology, Guangdong Provincial Hospital of Chinese Medicine, Guangzhou 510006. 4. Department of Nephrology, Henan Provincial People’s Hospital, Department of Nephrology of Central Fuwai Hospital, Zhengzhou 450003. 5. Guangdong Provincial Key Laboratory of Chinese Medicine for Prevention and Treatment of Refractory Chronic Diseases, Guangzhou 51006. 6. Guangdong Provincial Key Laboratory of Clinical Research on Traditional Chinese Medicine Syndrome, Guangzhou 51006
Clc Number:R-33
Fund Project:

Article

Figures

Metrics

Reference

Cited by

Materials

Comments

Abstract:

Objective Establish a reasonable and stable rat model of uric acid nephropathy to provide a pathological model for screening, research, and treatment of uric acid nephropathy. Methods Experimental rats were randomly divided into three model groups and a control group. Model mice were administrated orally with 750 mg / kg oteracil potassium combined with 150 mg / kg low dose uric acid (M-A), 750 mg / kg oteracil potassium combined with 300 mg / kg medium dose uric acid (M-B), or 750 mg / kg oteracil potassium combined with 600 mg / kg high dose uric acid (M- B). After continuous intragastric administration for 4 weeks, changes in blood uric acid, blood creatinine, urea nitrogen, triglycerides, cholesterol and other indicators as well as pathological changes of the kidneys were observed for 4 weeks. Results Compared with the control group, the serum uric acid of the three model groups was significantly higher (P< 0.01, P<0.05, P<0.05), serum creatinine of the M-B and M-C groups was increased significantly (P<0.05, P<0. 01), triglycerides of the M-B group were significantly lower (P<0.05). Renal pathology scores of M-B and M-C groups were significantly higher those of the control group (P<0.01). Masson staining of morphology showed that, in comparison with the control group, kidney damage was more obvious in the three model groups ( P< 0.05, P< 0.01, P< 0.01 ). Immunohistochemical staining of inflammation marker CD68 showed that, compared with the control group, its expression was increased of in three model groups (P<0. 05, P<0. 01, P<0. 01). Expression of epithelial cell marker E-Cadherin was significantly reduced in M-B and M-C groups in comparison with to the control group ( P< 0.01 ). Expression of myofibroblast marker protein α-SMA was increased the three model groups compared with the control group (P<0.05, P< 0.01, P<0.01). Conclusions Oteracil potassium (750 mg / kg) combined with the middle dose of uric acid (300 mg / kg) is ideal to establish a rat model of uric acid nephropathy.

Key words:rats; potassium oxonate; uric acid; uric acid nephropathy; animal models

Get Citation

Copy

Article Metrics

Abstract:
PDF:
HTML:
Cited by:

History

Received:January 28,2021
Revised:
Adopted:
Online: April 12,2022
Published:

Home

About this journal

Editorial Board

Info for Author

Contact Us

中文版

Get Citation

Share

Article Metrics

History

Article QR Code